Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2022-08-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
2022年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a company (海创药业股份有限公司) about the management and actual use of funds raised in the first half of 2022. It includes specifics on the amount raised, usage of funds, regulatory compliance, and investment projects funded by the raised capital. The document references regulatory guidelines related to fundraising and fund management, and it provides detailed financial figures and tables about the use of the raised funds. This matches the description of a Capital/Financing Update, which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report publication but contains substantive financial data and analysis about fundraising usage. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-08-29 Chinese
中信证券股份有限公司关于海创药业股份有限公司高级管理人员离职暨变更核心技术人员的核查意见
Board/Management Information Classification · 95% confidence The document is a detailed announcement from a securities company (CITIC Securities) regarding the departure of a senior management person and changes in core technical personnel at a company (Haichuang Pharmaceutical). It includes biographical details, impact assessment, and official opinions from the sponsor institution. The content focuses on management changes and personnel updates rather than financial results, regulatory certifications, or shareholder votes. It is not a full annual or interim report, nor an earnings release or audit report. The document fits the category of Board/Management Information (MANG) because it announces changes in senior management and core technical personnel with official verification and impact analysis.
2022-08-29 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年半年度报告' which translates to '2022 Half-Year Report'. It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and other comprehensive information typical of an interim or quarterly report. The report period is specified as January 1, 2022 to June 30, 2022, confirming it covers a period shorter than a full fiscal year. The document is lengthy (15,000 characters) and includes actual financial statements and substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net assets, net profit, cash flow, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive details. The document length is 3154 characters, which is relatively short and consistent with a summary rather than a full report. The content includes substantive financial data and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but contains actual financial figures and management discussion. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
关于高级管理人员离职暨变更核心技术人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a senior management member (clinical vice president and core technical personnel) and the appointment of a new core technical personnel. It details the departure, the handover of responsibilities, and the impact on the company. It also includes a verification opinion from the sponsoring institution. There are no financial statements, earnings data, or detailed financial analysis. The document is focused on management changes and personnel updates, specifically senior management and core technical staff. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2684 characters, which is typical for such announcements and not a full report or regulatory filing. Hence, the classification is MANG with high confidence.
2022-08-29 Chinese
独立董事关于公司第一届董事会第二十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of a company regarding two matters: a special report on the storage and use of raised funds for the half-year 2022, and the appointment of a senior management officer. The document references compliance with company law, stock exchange listing rules, and company articles. It does not contain full financial statements or detailed financial analysis, but rather expresses an independent opinion on specific agenda items from a board meeting. The document length is short (913 characters), and it is not a full report but an opinion related to board matters. This fits best under Board/Management Information (MANG), as it concerns management appointment and board meeting opinions. It is not an Annual Report, Interim Report, or Audit Report, nor is it a regulatory filing or announcement of a report publication. Therefore, the classification is MANG with high confidence.
2022-08-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.